Alumis Inc. (ALMS) reported an insider ownership change by Sanam Pangali in a Form 4 filed July 8, 2026, covering a transaction dated July 6, 2026. The filing reports a transaction involving Alumis common stock tied to 5,000 shares at $5.06 per share. The explanatory note indicates the securities are associated with an option award: 25% of the shares underlying the option vested on February 18, 2026, with the remaining shares scheduled to vest in equal monthly installments over the following 36 months. Continued vesting is subject to Pangali’s “Continuous Service” to Alumis, as defined under the company’s 2024 Equity Incentive Plan, and the award is also subject to possible acceleration. The filing text does not show a transaction code in the provided extract, nor does it provide a complete post-transaction beneficial ownership total for Pangali. Based on the vesting footnote, the reported action appears to involve an equity incentive option covering 5,000 shares of Alumis common stock with a $5.06 per-share price, rather than an open-market stock trade. Pangali signed the filing on July 8, 2026. The disclosure matters because it records insider equity compensation activity and provides investors with details about the timing, size, price, and vesting conditions of the insider’s Alumis-linked securities.
Stock detail
Alumis (ALMS) stock price, chart, and key data
View Alumis stock price, chart movement, and headline metrics on Woodstock's stock detail page.

Stock detail
Alumis
ALMS · XNAS
-$4.19 (-14.55%) past day
$24.61
Overnight $24.63 (+0.08%)
Key metrics
Earnings
Quarterly results and the next expected release
FY25 Q2
Q3
Q4
FY26 Q1
Q2
Q3
Day range
$26.99 - $29.02
Close price
$28.30
Market cap
$3.6B
P/E ratio
-33.26
About the company
Alumis Inc
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app